Comparative Pharmacology
Head-to-head clinical analysis: ROXICET versus ROXICET 5 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROXICET versus ROXICET 5 500.
ROXICET vs ROXICET 5/500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Roxicet is a combination of oxycodone, a full mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, to reduce pain perception and fever.
Oxycodone is a full opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and producing analgesic and antipyretic effects.
1-2 tablets (oxycodone 5-10 mg/acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4000 mg/day (3000 mg/day in high-risk patients).
1-2 tablets (5-10 mg oxycodone / 325-650 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 12 tablets per day (60 mg oxycodone / 6000 mg acetaminophen) in 24 hours.
None Documented
None Documented
Oxycodone: 3-5 hours (immediate-release); prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours.
Oxycodone: 3-5 hours (immediate-release); Acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged (up to 12-15 hours).
Primarily renal (90% as glucuronide conjugates, <10% unchanged). Biliary/fecal excretion is minor (<5%).
Oxycodone: primarily hepatic metabolism to noroxycodone, oxymorphone, and conjugates; renal elimination of metabolites (about 60-87% as unchanged and metabolites), fecal < 10%. Acetaminophen: renal elimination of conjugates (90-100%), <5% unchanged.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination